• mAbxience and Egis collaborate on the commercialization of two biosimilar candidates • The agreement covers eight Central and Eastern European countries with the potential for expansion into additional territories • mAbxience will serve as the marketing authorization holder, while Egis will manage commercialization in the designated regions

Continuous modernisations and investment, launch of a new line of business, tree planting, exhibitions, and a short story contest. In 2023 Egis commemorated its 110th anniversary with a special series of events.

Egis and the Uzbek Medicines Authority have signed a collaboration agreement in Tashkent to improve pharmaceutical regulations and access to medicines in Uzbekistan.

The selection process for the position of Egis Group’s Commercial Director has been closed. As a result, dr Csaba Pácz remains head of the Commercial Directorate.

The predecessor of Egis Pharmaceuticals PLC, Dr Wander Pharmaceuticals and Nutriments Ltd. was registered on 19 February 1913.

Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.

The inspiring work environment of Egis Trade Centre, located on Lehel Street, won the Office of the Year campaign’s annual award in the category of Community Space of the Year.

We have commemorated World Cancer Day.

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

This March marks the official start of the Hungarian Nationwide Public Health Screening Program’s special campaign: the new initiative focuses on children’s health.

Health means more than just the lack of illnesses.

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

Egis Pharmaceuticals PLC, celebrating the 110th anniversary of its foundation this year, is expanding its usual activities with new elements thanks to investments exceeding a total value of more than 100 billion HUF in Hungary over the past period.. Egis, one of the leading generic pharmaceutical companies in Eastern and Central Europe, now offers drug stubstance contract development and contract manufacturing services under the name of Egis Pharma Services to both existing and new pharmaceutical partners.

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

Disinfection plays an important role in reducing the risk of infection. As a responsible company, Egis supports the safe operation of pharmacies in the second wave of the coronavirus pandemic as well.

У тісній співпраці з нашими працівниками ми зараз працюємо над переробкою захисного одягу. Незважаючи на те, що проект ще триває, наша співпраця вже була визнана: нам було присуджено премію за добру практику на здорових робочих місцях, щоб ми могли перейти до наступного туру, організованого для країн ЄС.

It is the third time our company supports the Hungarian Press Photo Exhibition’s Nature and Science category.

According to our mission, we serve people with all of our skills, so that they can live a long and healthy life. That is why we chose to support the comprehensive nationwide screening program as a Golden Sponsor in 2019. The state-of-the-art screening truck will tour around the country until Christmas, stopping by 200 spots to offer screenings in 37 different areas.

The Hungarian Innovation Association, in collaboration with the Hungarian Innovation Foundation, announced the contest for the 2024 Innovation Grand Prize at the Egis Science and Technology Center. The significance of the award is highlighted by the fact that innovative companies can apply for the 33rd time for the competition, which will conclude with a ceremonial award ceremony next spring.

On the occasion of the national holiday, Dr. István Hodász, CEO of Egis was granted the award ‘For the Hungarian Economy’ by Deputy Prime Minister and Minister of Finance Mihály Varga. The award is the most prestigious recognition to be given by the Minister of Finance on ministerial level for outstanding excellence and contribution to the Hungarian economy.

One of Egis’ core values is care – with our immediate surroundings as well as in a wider sense. As a responsible company, we strive to support such projects that serve people’s safety and comfort. In this spirit, Egis decided to support the construction of a safe bicycle railroad crossing that is used also by many of our employees daily on their way to our Körmend plant.

Virtual driving, concerts for children, jewelry DIY workshop, health pavilion, Dénes Pál on stage – it’s hard to list all the programs that Egis Family Day awaited our employees with.